<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906031</url>
  </required_header>
  <id_info>
    <org_study_id>FirstJinanU_SSG</org_study_id>
    <nct_id>NCT04906031</nct_id>
  </id_info>
  <brief_title>Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations</brief_title>
  <official_title>Sodium Stibogluconate in the Myelodysplastic Syndromes/Acute Myeloid Leukemia With One of the 65 Defined p53 Mutations That Can be Functionally Rescued by Sodium Stibogluconate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Jinan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Jinan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of&#xD;
      myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined&#xD;
      list. The list includes 65 p53 mutations that were experimentally confirmed to be&#xD;
      pharmacologically restored with tumor-suppressive function by antimonials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      p53 is inactivated by over hundreds of diverse mutations in cancer. The investigator&#xD;
      purposefully selected the phenotype-reversible temperature-sensitive (TS) p53 mutations for&#xD;
      pharmacological rescue, and pertinently used p53 thermostability as readout to screen for TS&#xD;
      p53 mutation rescue compounds. By this, the investigator identified antiparasitic drug&#xD;
      antimonials efficiently thermostabilized the TS mutants by noncovalent binding. The&#xD;
      antimonials met the three go-to criteria as a targeted drug-availability of co-crystal&#xD;
      structure, structure model-compatible Structure-Activity Relationship, and target&#xD;
      (p53)-specificity in cells, and consequently extended survival of xenograft mouse with TS p53&#xD;
      mutant.&#xD;
&#xD;
      Under the clinical antiparasitic dosage, the antimonials effectively rescued TS p53 mutant in&#xD;
      patient-derived primary acute myeloid leukemia cells. Scan of the most frequent 815 p53&#xD;
      missense mutations identified 65 of them, predominantly TS mutations, as the&#xD;
      antimonial-treatable mutations. Thus, the trial aims to evaluate the safety and effectiveness&#xD;
      of the approved antimonial-Sodium Stibogluconate-in the treatment of myelodysplastic&#xD;
      syndrome/acute myeloid leukemia (MDS/AML) with the 65 antimonial-treatable p53 mutants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 28 days)</time_frame>
    <description>Partial response (PR) + complete response (CR) rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>At the end of Cycle 4 (each cycle is 28 days)</time_frame>
    <description>Adverse events (AEs) will be reported and graded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myeloid Malignancy</condition>
  <condition>Temperature-Sensitive p53 Mutation</condition>
  <condition>Sodium Stibogluconate</condition>
  <condition>P53 Mutation</condition>
  <arm_group>
    <arm_group_label>Sodium stibogluconate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium stibogluconate</intervention_name>
    <description>Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.</description>
    <arm_group_label>Sodium stibogluconate</arm_group_label>
    <other_name>SSG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically confirmed myelodysplastic syndrome (MDS) or acute myeloid leukemia&#xD;
             (AML).&#xD;
&#xD;
          2. Patients with one of the 65 antimonial-treatable p53 mutations with &gt; 5% VAF: Q136P,&#xD;
             Y234H, V272M, F270V, P278A, R213L, Y126H, T253N, T253I, R158L, Q136E, P142F, A129D,&#xD;
             L194R, R110P, V172G, C176F, I254N, K305R, E285D, T155P, H296D, E258G, G279V, T211A,&#xD;
             R213P, C229Y, I232F, E294K, P152R, R196P, M160T, N131S, N131H, K139N, L330H, Y220N,&#xD;
             E298Q, D148E, L264R, E224D, H168P, N263H, K320N, S227C, E286D, K292T, V203A, M237R,&#xD;
             F212L, K132Q, Y236S, Y126S, Q136H, E221A, I232S, Y163H, P190T, C182Y, P142L, Y163S,&#xD;
             V218E, I195S, V272A, and S106R.&#xD;
&#xD;
          3. Life expectancy &gt;12 weeks.&#xD;
&#xD;
          4. ECOG Performance status &lt; 3.&#xD;
&#xD;
          5. Aged from 18 to 75.&#xD;
&#xD;
          6. Active bone marrow hyperplasia indicated by morphology.&#xD;
&#xD;
          7. Normal liver and renal function, bilirubin ≤35μmol/L, ASL/ALT lower than 2xULN,&#xD;
             creatinine level ≤150μmol/L.&#xD;
&#xD;
          8. Normal cardiac function.&#xD;
&#xD;
          9. Lung function: dyspnea ≤ CTC AE grade 1 and SaO2≥ 92% in indoor air environment.&#xD;
&#xD;
         10. Written Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed CNS involvement.&#xD;
&#xD;
          2. Severe cardiac diseases including myocardial infarction or heart insufficiency.&#xD;
&#xD;
          3. QT interval ≥450ms on ECG.&#xD;
&#xD;
          4. With other visceral malignancy.&#xD;
&#xD;
          5. Active tuberculosis or HIV(+).&#xD;
&#xD;
          6. Patients with pregnancy or lactation.&#xD;
&#xD;
          7. Allergic or significantly contraindicated to any drugs involved in intervention.&#xD;
&#xD;
          8. Previous intolerance or allergy history to similar drugs.&#xD;
&#xD;
          9. Participation at same time in another study in which investigational drugs are used.&#xD;
&#xD;
         10. Any other conditions interfering the study.&#xD;
&#xD;
         11. Abnormal liver function which does not meet the inclusion criteria.&#xD;
&#xD;
         12. ECOG performance status ≥3, CCI &gt;1, ADL &lt;100.&#xD;
&#xD;
         13. Aged &lt;18 years or &gt;75years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Lu, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui Zeng, MD</last_name>
    <phone>+86 18002201919</phone>
    <email>androps2011@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huien Zhan, MD</last_name>
    <phone>+86 15084958382</phone>
    <email>zhanhuien@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510632</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Zeng, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Jinan University</investigator_affiliation>
    <investigator_full_name>Hui Zeng</investigator_full_name>
    <investigator_title>Director of Hematology Department of the First Affiliated Hospital of Jinan University</investigator_title>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myeloid Malignancy</keyword>
  <keyword>Temperature-sensitive p53 Mutations</keyword>
  <keyword>Sodium Stibogluconate</keyword>
  <keyword>p53</keyword>
  <keyword>precision medicine</keyword>
  <keyword>antimonial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antimony Sodium Gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

